{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:06Z","timestamp":1791685326057,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"vor","delay-in-days":1881,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> During the last decade, a systematic effort to develop a pharmacological treatment for Alzheimer disease (AD) has resulted into three drugs being registered for the first time in the USA and Europe for this specific indication. All three are cholinesterase inhibitors (ChEI). The major therapeutic effect of ChEI on AD patients is to maintain cognitive function at a constant level during a six\u2010month to one\u2010year period of treatment, as compared to placebo. Additional drug effects might slow cognitive deterioration and improve behavioral and daily living conditions. Comparison of clinical effects of six ChEI demonstrates a rather similar magnitude of improvement in cognitive measures. For some drugs, this may represent an upper limit, whereas for other it may still be possible to further increase the benefit. In order to maximize and prolong positive drug effects, it is important to start early and adjust dosage during the treatment. Recent studies show that in many patients the stabilization effect produced by ChEI can be prolonged for as long as a 24\u2010month period. In order to explain the stabilizing effect of ChEI, a mechanism other than AChE inhibition, based on \u03b2\u2010amyloid metabolism, is postulated.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2000.tb06942.x","type":"journal-article","created":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T22:05:35Z","timestamp":1279663535000},"page":"321-327","source":"Crossref","is-referenced-by-count":99,"title":["Cholinesterase Inhibitors Stabilize Alzheimer's Disease"],"prefix":"10.1111","volume":"920","author":[{"given":"EZIO","family":"GIACOBINI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"e_1_2_3_2_2","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1001\/jama.1992.03490180055026","article-title":"Controlled trial of tacrine in Alzheimer's disease","volume":"268","author":"Farlow M.","year":"1992","journal-title":"J. Am. Med. Assoc."},{"key":"e_1_2_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510370037029"},{"key":"e_1_2_3_4_2","first-page":"49","article-title":"Clinical trials and therapeutics: relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease","volume":"15","author":"Canal I.","year":"1996","journal-title":"Clin. Pharmacol. Therap."},{"key":"e_1_2_3_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.4.700"},{"key":"e_1_2_3_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000106895"},{"key":"e_1_2_3_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.1.136"},{"key":"e_1_2_3_8_2","first-page":"279","article-title":"Treatment of Alzheimer's disease","volume":"3","author":"Doody R.S.","year":"1998","journal-title":"Neurologist"},{"key":"e_1_2_3_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000017126"},{"key":"e_1_2_3_10_2","doi-asserted-by":"crossref","unstructured":"Anand R. R.D. Hartman & P.E. Haves. 1996. An overview of the development of SDZ ENA 713 a brain selective cholinesterase inhibitor disease.InAlzheimer Disease: From Molecular Biology to Therapy. R. Becker & E. Giacobini Eds.: 239\u2013243. Birkh\u00e4user. Boston MA.","DOI":"10.1007\/978-1-4612-4116-4_35"},{"key":"e_1_2_3_11_2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial","volume":"318","author":"Rossler M.","year":"1999","journal-title":"Br. Med. J."},{"issue":"5","key":"e_1_2_3_12_2","first-page":"391","article-title":"Rivastigmine","volume":"1","author":"Spencer M.C.","year":"1998","journal-title":"a review of its use in Alzheimer's Disease. Drugs & Aging"},{"key":"e_1_2_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199601030-00003"},{"key":"e_1_2_3_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5.1222"},{"key":"e_1_2_3_15_2","first-page":"318","article-title":"The effects of Metrifonate on the cognitive, behavioraland functional performance of Alzheimer's disease patients","volume":"60","author":"Raskind M.","year":"1999","journal-title":"J. Clin. Psychol."},{"key":"e_1_2_3_16_2","unstructured":"Farlow M.R P.A. Cyrus & B. Gulanski. 1998. Metrifonate improves the cognitive deficits of Alzheimer's disease patients in a dose\u2010related manner. Am. Geriatr. Soc. Meeting Seattle Abstr. A15."},{"key":"e_1_2_3_17_2","unstructured":"Wilkinson D. 1997. Galanthamine hydrobromide\u2010results of a group study. Eighth Congress Int. Psychoger. Jerusalem. Abstr. 7025."},{"key":"e_1_2_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199903000-00003"},{"key":"e_1_2_3_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.6.1146"},{"key":"e_1_2_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(97)00124-1"},{"key":"e_1_2_3_21_2","unstructured":"Giacobini E. 2000. Cholinesterase and cholinesterase inhibitors. From molecular biology to therapy. Chapter 12. Martin Dunitz Publishers. London."},{"key":"e_1_2_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199503000-00012"},{"key":"e_1_2_3_23_2","doi-asserted-by":"crossref","unstructured":"Giacobini E. 1996. Cholinesterase inhibitors do more than inhibit cholinesterase.InAlzheimer Disease: From Molecular Biology to Therapy. R. Becker & E. Giacobini Eds.: 187\u2013204. Birkh\u00e4user. Boston MA.","DOI":"10.1007\/978-1-4612-4116-4_29"},{"key":"e_1_2_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80108-7"},{"key":"e_1_2_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1996.tb39060.x"},{"key":"e_1_2_3_26_2","unstructured":"Small D.H. G. Sberna Q.X. Liet al.The beta\u2010amyloid protein influence on acethyl\u2010cholinesterase expression assembly and glycosylation. Sixth Int. Conf. on Alzheimer's Disease and Related Disorders. Amsterdam."},{"key":"e_1_2_3_27_2","first-page":"1105","article-title":"Amyloid\u2010beta peptide induces cyclooxygenase\u20102 expression and activity in brain\u2010derived cells","volume":"25","author":"Hilfers M.A.","year":"1999","journal-title":"Soc. Neurosci."},{"key":"e_1_2_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(97)00079-5"},{"key":"e_1_2_3_29_2","unstructured":"Jelic V. K. Amberla O. Almkvistet al.1998. Long\u2010term tacrine treatment slows the increase of theta power in the EEG of mild Alzheimer patients compared to untreated controls. Fifth Int. Geneva\/Springfield Symposium on Advances in Alzheimer Therapy. Geneva. Abstr. 147."},{"key":"e_1_2_3_30_2","unstructured":"Anand R. R. Hartman J. Messinaet al.1998. Long\u2010term treatment with rivastigmine continue to provide benefits for up to one year. Fifth Int. Geneva\/Springfield Symposium on Advances in Alzheimer Therapy. Geneva. Abstr. 18."},{"key":"e_1_2_3_31_2","first-page":"197","article-title":"Long\u2010term cognitive benefit from galanthamine in Alzheimer's disease","volume":"1","author":"Rainer M.","year":"1999","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"e_1_2_3_32_2","unstructured":"Winblad B. K. Engedal H. Soininenet al.1999. Donepezil enhances global function cognition and activities of daily living compared with placebo one year. 12th Congr. ECNP. Abstr. 30. London."},{"key":"e_1_2_3_33_2","doi-asserted-by":"crossref","unstructured":"Mohs R. R. Doody J. Morriset al.1999. Donepezil preserves functional status in Alzheimer's disease patients. Eur. Neuropsychol. Suppl 5 Abstr. S328.","DOI":"10.1016\/S0924-977X(99)80460-X"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2000.tb06942.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2000.tb06942.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T03:41:17Z","timestamp":1695699677000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2000.tb06942.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10.1111\/j.1749-6632.2000.tb06942.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb06942.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}